UCSF_CAPRA_prostate_cancer_risk v.1
The UCSF CAPRA score for prostate cancer risk provides an outcome prediction for patients with prostate cancer, post treatment
The UCSF (University of California, San Francisco CAPRA (CAncer of the Prostate Risk Assessment) Score uses PSA values and Gleason score grades/patterns among other indicators, to help predict prognosis for patients with prostate cancer.
The tool sums the individual variables for a score ranging from 0 to 10. The variables are: Gleason grade/pattern (either 4/5 (primary or secondary) or not) PSA values at diagnosis Age Clinical stage of prostate cancer: either 1/2 or 3a are assessed Percent biopsy cores positive for cancer. Managment: - For very low risk patients, consider routine surveillance. - For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy). - For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy). - For very high-risk patients, consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment. Score interpretation: Metastasis-free interval Prostate cancer–specific survival Overall survival % likelihood (95% CI) % likelihood (95% CI) % likelihood (95% CI) CAPRA Risk Group 5-year 10-year 5-year 10-year 5-year 10-year Low Risk Group 99.3 97.5 99.7 97.1 92.5 71.4 (0-2 points) Intermediate Risk 96.9 93.3 98.6 91.6 90.2 59.7 Group (3-5 points) High Risk Group 90.4 83.4 93.4 79.1 78.7 42.0 (≥6 points)
Do not use for diagnostic purposes without also considering a thorough clinical investigation.
Ref. 1: Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI Journal of the National Cancer Institute. 2009;101(12):878-887. doi:10.1093/jnci/djp122.
openEHR-EHR-OBSERVATION.basic_demographic, openEHR-EHR-OBSERVATION.lab_test_psa, openEHR-EHR-OBSERVATION.gleason_score_for_prostate_cancer, openEHR-EHR-OBSERVATION.prostate_cancer_tnm_staging, openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk, openEHR-EHR-EVALUATION.ucsf_capra_for_prostate_cancer_assessment
